Editas Medicine, Inc. Profile Avatar - Palmy Investing

Editas Medicine, Inc.

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops …

Biotechnology
US, Cambridge [HQ]
Growth Rates · Payout · Yield

Dividends Over Time

  • Records
  • Forecasts [Soon]
Growth Rates
% YoY
% 3Yr
% 5Yr
% 10Yr
Key Metrics
- -% TTM Yield
- - Average Days Gap
Series
% - - Yield
0.00% Payout Ratio
Cash Amount Pay Date
Cash Amount Pay Date
End of EDIT's Analysis
CIK: 1650664 CUSIP: 28106W103 ISIN: US28106W1036 LEI: - UEI: -
Secondary Listings
EDIT has no secondary listings inside our databases.